JB/PUT/BIONTECH ADR/100/0.025/20.09.24 | Real-time Bid/Ask 08:58:23 2024-06-26 EDT | ||
| 0.37 CHF / 0.38 CHF | +10.29% |
|
| Current month | +88.89% | ||
| 1 month | +61.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIONTECH SE
Latest news about BIONTECH SE
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 0.34 | +3.03% |
| 24-06-24 | 0.33 | -8.33% |
| 24-06-21 | 0.36 | +5.88% |
| 24-06-19 | 0.34 | +6.25% |
| 24-06-18 | 0.32 | +10.34% |
Delayed Quote Swiss Exchange
Last update June 25, 2024 at 11:20 am
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIONTECH SE |
| Issuer | Bank Julius Bär |
| BNYJJB | |
| ISIN | CH1303723543 |
| Date issued | 2023-11-23 |
| Strike | 100 $ |
| Maturity | 2024-09-20 (86 Days) |
| Parity | 40 : 1 |
| Emission price | 0.33 CHF |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.38 CHF |
|---|---|
| Lowest since issue | 0.15 CHF |
| Delta | -0.77x |
| Omega | 3.991 |
| Premium | 0.81x |
| Gearing | 5.18x |
| Moneyness | 1.185 |
| Difference Strike | 15.62 $ |
| Difference Strike % | +15.62% |
| Spread | 0.01 CHF |
| Spread % | 2.70% |
| Theoretical value | 0.3650 |
| Implied Volatility | 38.72 % |
| Total Loss Probability | 17.60 % |
| Intrinsic value | 0.3497 |
| Present value | 0.0153 |
| Break even | 83.70 CHF |
| Theta | -0x |
| Vega | 0x |
| Rho | -0x |
Company Profile
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
Consensus: BioNTech SE
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
78.84
EUR
Average target price
103.5
EUR
Spread / Average Target
+31.24%
- Stock Market
- Warrants
- BNYJJB Warrant
